Toulouse, France

Daniel Frehel

This inventor holds 22 USPTO granted patents, primarily in Pharmaceutical Chemistry. Top assignees: Sanofi, Elf Sanofi, Parcor. Active years: 1978-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Daniel Frehel. Retrieved from https://idiyas.com/inventor/daniel-frehel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 90.9

Average Co-Inventor Count = 3.6

ph-index = 8

Forward Citations = 231(Granted Patents)


Location History:

  • Toulouse, FR (1978 - 1998)
  • alle de Barcelone, FR (1998)
  • Estadens, FR (2007 - 2011)

Company Filing History:


Years Active: 1978-2011

Loading Chart...
Areas of Expertise:
Acylaminothiazole Derivatives
Thieno-Pyridinone Compounds
Polysubstituted Benzodiazepines
Glycinamide Derivatives
Ischemic Event Prevention
Anti-Inflammatory Agents
Heterocyclic Compounds
Pharmaceutical Preparation
Thienocyclopentanone Oximes
Dextro-Rotatory Enantiomers
Thieno-Pyridine Derivatives
22 patents (USPTO):Explore Patents

Title: **Daniel Frehel: Innovator in Therapeutic Patents**

Introduction

Daniel Frehel is a prominent inventor located in Toulouse, France, known for his contributions to the field of therapeutics with a total of 22 patents to his name. His innovative work focuses on developing acylaminothiazole derivatives, which hold significant promise for therapeutic applications.

Latest Patents

Among his latest patents, Frehel has disclosed and claimed various therapeutic uses of compounds corresponding to a specific general formula. These compounds utilize acylaminothiazole derivatives, which have been described with precision in terms of their components and potential health benefits. Frehel's application details the compounds' structure, including variations where R represents different chemical groups, showcasing his deep understanding of medicinal chemistry.

Career Highlights

Frehel has built a notable career through his work with reputable companies such as Sanofi and Elf Sanofi. His innovative contributions within these organizations have significantly advanced the development of therapeutic drugs, directly impacting patient care and treatment options.

Collaborations

Throughout his career, Frehel has collaborated with various talented individuals in his field. Notable coworkers include Jean-Pierre Maffrand and Alain Badorc, who have contributed to the successful development and patenting of therapeutic innovations alongside Frehel.

Conclusion

In summary, Daniel Frehel has established himself as a key figure in the landscape of pharmaceutical innovation through his 22 patents and impactful collaborations. His latest developments in acylaminothiazole derivatives highlight the potential for new therapeutic applications, reflecting his dedication to advancing medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…